semaj83/ctmatch_classification huggingface dataset:
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anal Neoplasm Negative screening test for HIV-1/2 within 30 days of Dose 1 Confirmed anal or anal/peri-anal HPV-16/18 infection at Screening by polymerase chain reaction (PCR) from HSIL specimen Anal tissue specimen/slides for diagnosis must be collected within 10 weeks of first dose of VGX-3100 At least one anal or anal/peri-anal (AIN2/3 and/or PAIN2/PAIN3) lesion that is histologically-confirmed as HSIL at Screening Appropriate candidate for histology collection procedures (i.e. excision or biopsy) as judged by the Investigator Female subjects must be post-menopausal, surgically sterile or agree to avoid pregnancy by continued abstinence or use of a contraceptive method with failure rate of less than 1% per year from Screening to one month after last dose of study medication (Week 12 or Week 40) Men who could father a child must agree to use at least one form of birth control during or continued abstinence from heterosexual intercourse prior to the study, for the duration of study participation and one month after last dose of study medication Normal Screening electrocardiogram (ECG)  Untreated micro invasive or invasive cancer Biopsy-proven Vaginal Intraepithelial Neoplasia (VAIN) and not undergoing medical care and/or treatment for VAIN Biopsy-proven Vulvar Intraepithelial Neoplasia (VIN) and not undergoing medical care and/or treatment for VIN Biopsy-proven Cervical Intraepithelial Neoplasia (CIN) 2/3 and not undergoing medical care and/or treatment for CIN Biopsy-proven Penile Intraepithelial Neoplasia (PIN) and not undergoing medical care and/or treatment for PIN Anal or anal/peri-anal HSIL that is not accessible for sampling by biopsy instrument Intra-anal and/or peri-anal lesion(s) that cannot be fully visualized at Screening Inability to have complete and satisfactory high resolution anoscopic exams (HRAs) Any treatment for anal or anal/peri-anal HSIL (e.g. surgery) within 4 weeks of Screening Pregnant, breast feeding or considering becoming pregnant within one month following the last dose of study medication
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 21.0-75.0,  Posttraumatic Stress Disorder Veteran of the U.S. Armed Forces Current diagnosis of PTSD (as documented in clinical chart and/or per participant report; a rule out diagnosis from a VA provider accompanied by a referral to the VA PTSD Outpatient Clinic (POC) will also be considered sufficient for inclusion) Woman of childbearing potential must agree to abstain from sexual relations that could result in pregnancy or use an effective method of birth control acceptable to both participant and study clinician during the study. Men are not required to use contraception during the study  Psychiatric Any known diagnosis of a primary psychotic or major neurocognitive disorder, including schizophrenia, brief psychotic disorder, or Alzheimer's or other dementia, as well as bipolar type I Severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to participant or others Note: Nonsuicidal depression comorbid with PTSD will not be exclusionary. Participants may continue in any concurrent psychotherapy or pharmacotherapy in which they are participating, other than pharmacotherapeutic agents specifically listed above. Participants with active suicidal ideation or with depression severe enough to require psychiatric hospitalization will be excluded Medical Significant bilateral visual loss (would preclude performing the PLR measurements) Current pregnancy or lactation Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist Acute or unstable chronic medical illness, including unstable angina, recent myocardial infarction (within 6 months), congestive heart failure, preexisting hypotension (systolic <110) or orthostatic hypotension (systolic drop > 20mmHg after two minutes standing or any drop accompanied by dizziness); autoimmune disorders; insulin-dependent diabetes Chronic renal or hepatic failure, acute pancreatitis, Meniere's disease, benign positional vertigo, or narcolepsy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 9.0-26.0,  Papillomavirus Infections Uterine Cervical Neoplasms Vulvar Neoplasms Vaginal Neoplasms Adenocarcinoma in Situ Condylomata Acuminata In good physical health Participants 9 to 15 years of age: has not had coitarche and do not plan on becoming sexually active during the study Participants 16 to 26 year of age: has never had Papanicolaou (Pap) testing or has had only normal Pap test results. Has a lifetime history of ≤4 male and/or female sexual partners Female participants 16 to 26 years of age: has not had sex with males or has had sex with males and used effective contraception, and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (rhythm method, withdrawal, and emergency contraception are not acceptable methods of contraception per-protocol)  Known allergy to any vaccine component, including aluminum, yeast, or History of severe allergic reaction that required medical intervention Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections Concurrently enrolled in clinical studies of investigational agents Immunocompromised or has been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition Had a splenectomy User of recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use History of a positive test for HPV Male participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata) or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer Female participants 16 to 26 years of age: history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia or worse)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carcinoma Neoplasia; Intraepithelial, Cervix Glandular Neoplasms Epithelial Neoplasm Neoplasms Patients that meet the diagnostic criteria. 2. Patients with age ≥18 years. 3. Patients with residual lesion greater than 3 mm after the initial punch, measurable by video colposcopy and with major changes (Criteria from Rio 2011). 4. Patients that have a positive test to the oncogenic virus of the human papilloma (16, 18, 31, 33, 45, 52 and 58). 5. Patients who give their informed consent to participation in writing. 6. Patients who consent to perform the conization according to the study schedule. 7. Patients with normal laboratory parameters within the limits established in the institution (complete blood count, platelets and erythrosedimentation. In the case of male sex (vasectomy, use of condoms) while the treatment lasts  Patients who have received surgical, ablative, radiant, immunomodulatory or chemotherapy treatment 30 days before recruitment. 2. Patients pregnant or breastfeeding. 3. Patients with acute cervico-vaginal infections. 4. Patients with positive serology known to HIV and/or syphilis. 5. Patients with diseases that compromise the state of consciousness or their possibility of collaboration. 6. Patients with a history of severe allergic history. 7. Patients who are participating in another research
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  LGBT Health Cultural Competency Education Sexual Orientation Gender Identity years or older Clinical staff or patient at participating clinical site (for staff interviews and web surveys) English speakers  Does not meeting the above
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  the High-Risk HPV Infection age not above 70 histologically diagnosed as HSIL or stage IA1 cervical squamous cancer received conization in Beijing Obstetrics and Gynecology Hospital HR-HPV infected without any treatment other than conization HR-HPV genotype tested before coniztion  age above 70 with severe desease that influence the follow-up received other treatment on cervical lesion data incompleted not meet the inclusive
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced CEACAM6-expressing Solid Tumors Male or female patients aged ≥ 18 years Patients with histologically confirmed advanced/ metastatic solid tumors: Dose escalation: solid tumor types with a expression of (gastric/ GEJ cancer, esophageal cancer, NSCLC, CRC, pancreatic cancer, cervical cancer, breast cancer, bladder cancer, head and neck squamous cell cancer, bile duct cancer); Dose expansion: advanced adeno NSCLC, CRC and gastric/ GEJ adenocarcinoma ECOG-PS of 0 to 1 Adequate organ function (bone marrow, liver, kidneys) Adequate coagulation function Adequate cardiac function  Patients with active symptomatic or untreated brain metastases; possible exceptions for patients with treated asymptomatic central nervous system metastases Active autoimmune disease History or evidence of active pulmonary fibrosis, organizing pneumonia, or pneumonitis Risk factors for bowel obstruction or bowel perforation History of cardiac disease Uncontrolled arterial hypertension despite optimal medical management Clinically relevant findings in electrocardiogram HIV infection Active HBV or HCV infection
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  High Grade Ovarian Serous Adenocarcinoma Stage III Ovarian Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 With suspected advanced ovarian cancer Planned surgery Have a uterus and no history of tubal occlusion  Unable to speak English Unable to provide informed consent Prior hysterectomy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Cervical Cancer Jamaican women, aged 30 to 65  Women who report having had a hysterectomy have had a history of cervical cancer Women who are currently up-to-date on cervical cancer screening (have had a Pap in the last 3 years or have had a Pap smear/HPV co-test within the past 5 years) Adults unable to consent, children, pregnant women and prisoners
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 50.0-60.0,  Exercise All women diagnosed as essential hypertension All women must be in their early postmenopausal period  Lesion to higher centers leading to hypertension (embolism) any cardiovascular disease premature menopause surgical menopause severe hypertension diabetic under treatment of hormonal therapy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Cardiovascular Diseases Written informed consent Programmed cardiac and noncardiac surgeries Need of invasive arterial blood pressure monitoring  Emergency surgeries Acute pulmonary diseases Arrhytmias Congestive cardiac failure
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-50.0,  HSIL of Cervix HSIL, High Grade Squamous Intraepithelial Lesions High-Grade Cervical Intraepithelial Neoplasia Human Papilloma Virus HIV Negative Cervical Cancer CIN - Cervical Intraepithelial Neoplasia Cervical Neoplasm Cervical Dysplasia Women, 25 to 50 years old. 2. Biopsy-confirmed cervical HSIL that is p16+ within 60 days of enrollment (dosing) with no evidence of invasive cancer in any specimen. 3. Colposcopy is satisfactory based on visualization of the entire squamo-columnar junction (SCJ). The borders of all lesions must be completely visible. 4. The upper limit of the visible (usually aceto-white) lesion is within 3 quadrants or less at screening  Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females. 2. HIV positive (tested at screening visit or within 3 months of screening visit). 3. Resolution of visible CIN lesion prior to enrollment. 4. ECC positive for glandular disease (adenocarcinoma in situ) or invasive cancer. 5. History of cervical cancer, colposcopy suspicious for cancer, any prior treatment of CIN, or hysterectomy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 8.0-99.0,  Healthy Cognitive Impairment Neurological Disorder Completed or will complete a BNA test Able to speak, read and understand English sufficiently to understand the nature of the study, and to allow completion of all study assessments Willingness to participate
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anal Squamous Intraepithelial Neoplasia HIV infection as confirmed by ELISA and western blot  Unable to provide informed consent
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anesthesia every patient who underwent a first conization procedure regardless of indication  patient's refusal to participate
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Wrinkle b. Symmetrical visible sign of aging involving at least a 9 cm2 area of the mid to low cheeks. c. Must be willing to give and sign a HIPPA form, photo consent and informed consent form. d. Must be willing to comply with study dosing and complete the entire course of the study. e. Female patients will be either of non-childbearing potential defined as: 1. Having no uterus 2. No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as: 1. Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 2. Intrauterine coil 3. Bilateral tubal ligation 4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 5. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active). 6. Vasectomized partner (must agree to use barrier method described above (4) if becomes sexually active with un-vasectomized). f. Negative urine pregnancy test results Baseline prior to study entry (if applicable)  Pregnant, planning pregnancy during the course of the study or breastfeeding 2. Extremely Severe aging face with extensive photodamage 3. Previous use of any form of soft tissue augmentation in the treatment area within the past 12 months 4. Pre-existing medical or dermatologic condition in the treatment area that may affect the treatment or interpretation of treatment effect (at investigator discretion) 5. Presence of tattoo and/or scar in the treatment area that in the investigators opinion would interfere with study assessments 6. Use of oral/topical retinoids within 1 month of Baseline 7. Previous use of botulinum toxins in the treatment area within the past 6 months 8. Previous surgical procedure in the treatment area within the past 12 months 9. Presence or evidence of any conditions that in the opinion of the investigator might impede the subject's ability to give consent or comply with protocol requirements. 10. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study 11. History of non-compliance with clinical research protocols 12. Ablative laser resurfacing to on their face within 12 months 13. Non-ablative laser or light procedures to their face within the past 3 months 14. Known allergy to Restylane® Silk or any of its constituents
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-53.0,  Uterine Cervical Dysplasia Papillomavirus Vaccines (vaccinated group) Thai women aged 20-45 years at the time of HPV vaccination Received at least 1 dose of bivalent or quadrivalent HPV vaccine at least 5 years ago Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result) (control group) Thai women without history of HPV vaccination Received Pap smear result at their ages 20-45 years at least 5 years ago Willing to provide written informed consent and receive Pap smear & HPV genotyping (only for those who need specimen collection for cervical cytology and HPV genotyping result)  Known pregnancy History of hysterectomy or excisional treatment of the cervix Known increased risk of bleeding Not willing to provide written informed consent
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Cervical Intraepithelial Neoplasia patients who underwent a loop electrosurgical excision procedure (LEEP)  a diagnosis of micro-invasion or nonsquamous histology less than six months of follow-up incomplete information in their clinical charts
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Must be 18 years of age or over Must be diagnosed with Systemic Lupus Erythematosus (SLE) Must be exposed to hydroxychloroquine Must be enrolled at participating sites  Under 18 years of age Not diagnosed with SLE Not exposed to hydroxychloroquine Not enrolled at participating sites